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cohorts were traced for 20 years (4-year Markov cycles) with
55–76 year old patients in order to predict primary and second-
ary CV events. Quarterly titration in year one was set up to a
maximum dose of 20 mg RSV, 80 mg ATV, 80 mg SIM and
40 mg PRA based on TC target, whereas risk was calculated
using average TC : HDL-C ratio of the 1000 simulated patients,
with adjustment for Framingham’s hypothesized over-prediction
of Mexican risk. The economic analysis was done under private
sector perspective with a 5% and 1.5% discount rate for costs
and beneﬁts, respectively. Unitary costs were obtained from
NADRO (local wholesaler). Mexican Institute of Social Security
costs and data from a Delphi Panel were used to estimate
CV diseases’ private costs. Disability-adjusted life years gained
(DALYs) for each treatment regimen were estimated. Results are
shown in natural units, while costs are expressed in US dollars.
Sensitivity analysis included threshold, one-way scenarios and
probabilistic analysis. RESULTS: RSV 10 mg for the 20-year
horizon resulted in less primary and secondary events (197) and
deaths (42), per 1000 patients, more DALYs (14.97) and lower
per-patient treatment costs ($8134.57) than other statins on
equivalent doses. Hence, RSV 10 mg is highly cost-effective with
a cost per DALYs gained of $16,802.15 than comparators.
Sensitivity analysis showed the robustness of results. CONCLU-
SION: RSV is a cost-effective strategy: it yields fewer CV events,
resulting in fewer deaths and signiﬁcant economic saving for
both patients and institutions.
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OBJECTIVE: AVOID (Aliskiren in the Evaluation of Proteinuria
in Diabetes) was a multicentre, randomised, double-blind, six-
month study designed to assess the effect of adding aliskiren, an
oral direct renin inhibitor, to losartan and optimal antihyperten-
sive therapy (excluding ACE inhibitors), on the reduction in
urinary albumin to creatinine ratio (UACR) in patients with
hypertension, type 2 diabetes, and nephropathy. A cost-
effectiveness model was developed aiming to estimate the pro-
gression to end-stage renal disease (ESRD) and to project the
associated costs and clinical outcomes of aliskiren in the UK
setting. METHODS: A previously published Markov model of
diabetic nephropathy and ESRD was adapted to incorporate
treatment effects from AVOID, where aliskiren reduced mean
UACR versus placebo by 20% (p = 0.0009). Transition prob-
abilities from AVOID were used until patients reached UACR
>1,900 mg/g, with probabilities from the Irbesartan in Diabetic
Nephropathy Trial used thereafter. Direct medical costs were
based on UK pharmacy costs and published sources. Annual
discount rates of 3.5% were applied over the 20-year time
horizon. RESULTS: Short-term therapy beneﬁts associated with
aliskiren were projected to increase life expectancy by 0.0983
years (7.9175  0.0434 versus 7.8192  0.0369 years), improve
quality-adjusted life expectancy by 0.0878 quality-adjusted
life years (QALYs) (5.3038  0.0444 versus 5.2160  0.0391
QALYs) and reduce the cumulative incidence of ESRD by 2.51
percent (19.52% versus 22.03%) compared to placebo. An incre-
mental cost-effectiveness ratio of £12,073 per QALY gained was
calculated for aliskiren, which is well below the willingness-to-
pay threshold of the UK of £30,000 per QALY gained. Sensitivity
analysis where the clinical beneﬁt of aliskiren was extended
beyond UACR >1900 mg/g, proved to be a cost saving strategy.
CONCLUSION: Aliskiren would be considered cost-effective in
the UK setting when added to losartan therapy due to the addi-
tional renal protection provided and a reduced incidence of
ESRD.
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OBJECTIVE: To investigate the cost-effectiveness of a diagnostic
imaging strategy starting with magnetic resonance angiography
(MRA) enhanced with a blood pool agent versus strategies start-
ing with either MRA enhanced with conventional extracellular
agents or standard-DSA in severe peripheral arterial occlusive
disease (PAOD) in Canada. METHODS: A microsimulation
model focusing on “diagnostic conﬁdence” instead of “diagnos-
tic accuracy”, built by Kienbaum et al. (submitted for publica-
tion) for the European perspective was adapted to compare a
strategy with initial MRA with Gadofosveset to strategies with
either initial MRA with conventional extracellular contrast
media (standard-MRA) or a standard digital subtraction angiog-
raphy (standard-DSA) in the work-up of severe PAOD (critical
limb ischemia) in the Canadian setting. The model allows evalu-
ating aggregated mean costs per initial diagnostic modality as
well as incremental costs per quality-adjusted life year (QALY)
gained. Both efﬁcacy and utility data were derived from the
European analysis. Cost data were calculated from the payer
perspective and estimated by the ‘Program for the Assessment
of Technology in Health’ (PATH) at McMaster University.
RESULTS: The model simulation predicts an equivalent utility
score for all alternatives considered. From the payer perspective,
the mean overall cost of the Gadofosveset-MRA strategy amount
to $7814. In contrast, aggregated costs with either standard-
MRA or -DSA reach $8637 and $9842, respectively. Thus, an
imaging strategy with initial Gadofosveset-MRA is less costly
than strategies initially using standard-MRA or -DSA. With
regard to cost-effectiveness the additional costs per QALY gained
by standard-MRA versus Gadofosveset-MRA amount to about
$117,000 and about $178,000 for standard-DSA. The model
was robust regarding probabilistic variations of all parameters.
CONCLUSION: From the payer perspective in Canada, an
imaging strategy starting with Gadofosveset-MRA represents a
cost-effective option for the diagnostic work-up of severe PAOD
(critical limb ischemia) compared to strategies with either
standard-MRA or -DSA.
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OBJECTIVE: Some new antidiabetic drugs such as insulin
glargine, insulin detemir, exenatide, and rosiglitazone have been
widely used in the clinical practice. Very few pharmacoeconomics
studies on diabetes medications are focused on these drugs. To
compare and contrast the cost-effectiveness of the various diabe-
tes medications, we conducted the systematic review of drug-
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related cost-effectiveness studies on diabetes. METHODS: A
literature search using PubMed and OhioLINK websites was
conducted for cost-effectiveness studies. The key terms used for
literature search were “diabetes”, and “cost, cost-effectiveness,
cost-beneﬁt, economics, or treatment outcome”. Eligible studies
were randomized controlled trials focusing cost-effectiveness of
diabetes drug therapies, published in English between July 2005
and October 2007. Review articles were excluded. RESULTS:
Initial search resulted in 911 abstracts. After applying the
inclusion/exclusion criteria, 11 studies were selected from
Canada, UK, USA, Austria, Germany and Asian regions. The
median sample size was 638 patients; the median duration of
trials was 39 weeks. Most studies demonstrated overall positive
effects in economic outcomes and found that interventions
improved the cost-effectiveness and health care utilization over
the control groups from their individual perspectives. Four
studies focused on insulin glargine, which together with other
new drugs including insulin detemir, exenatide and rosiglita-
zone can be more cost-effective. With regard to diabetes-related
complications such as renal disease, hypertension and diabetic
peripheral neuropathic pain, these studies suggest that the
earlier introduction of preventive measures such as therapeutic
drugs would lead to longer delays in the onset of its compli-
cations and the overall savings in health care resource utiliza-
tion. CONCLUSION: There is growing evidence that these
drug interventions may promote diabetic health with better
economic outcomes. The review complemented our previous
study of cost on diabetes till July 2005. Future research should
include extensive database search including databases such as
Cochran and manual search for the journals’ Diabetes, and
Diabetes Care.
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OBJECTIVE: Bradycardia-tachycardia syndrome (BTS) manage-
ment includes bradycardia and tachyarrhythmia therapy. Right
atrial appendage pacing (RAA), a typical pacing site, manages
bradycardia but have poor AF preventive properties. Biatrial
pacing (BiA) is a modality of pacing to prevent AF in BRT
patients with interatrial conduction disturbances. It is a cost-
effectiveness analysis of BiA versus RAA pacing in AF preven-
tion, in BTS patients. METHODS: Follow-up study: 125 pts (51
males, mean age = 67.9) with BTS, P-wave >120 ms and parox-
ysmal, recurrent AF; 50 pts had BiA and 75 RAA pacing system
implanted. Observation window was one year before pacemaker
implantation to three years after. Costs were calculated from the
public health care payer perspective. Primary clinical endpoints:
chronic AF occurrence and patient reported outcome reﬂecting
symptomatic AF episodes frequency at four point scale. AF epi-
sodes were deﬁned very frequent in case of AF episodes >1 per
week (rank 3), recurrent AF = 1 episode per week to 1 episode
per month (rank 2), occasional = if occurred <1 per month (rank
1), no recurrences = rank 0. Conﬁdence intervals for CER by
bootstrap method. RESULTS: The frequency of symptomatic AF
episodes decreased in BiA group as measured on the scale (2.54
vs 1.28; p < 0.001) and not in the RAA group (1.33 vs 1.55; NS).
There was 71.2% reduction of annual number of hospitaliza-
tions in BiA group; no change in RAA group as compared to
pre-implantation period. In BiA group 12.0% of patients devel-
oped chronic AF; 17.3% in the RAA group (NS). Incremental
cost-effectiveness ratio for decrease of AF frequency episodes
(BiA vs RAA) was 499.97 USD PPP (95%CI—272.5–1353.6) for
one point on the scale. CONCLUSION: Biatrial pacing in
contrast to RAA pacing decreases symptomatic AF episodes
frequency and hospitalizations. BiA compared to RAA pacing is
a cost-effective method of AF prevention in BTS patients with
pacing indications.
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OBJECTIVE: To assess whether bosentan is a cost-effective
ﬁrst-line treatment option compared with epoprostenol and
with no active intervention, all added to palliative care, for
patients with pulmonary arterial hypertension (PAH) of WHO
functional class (FC) III in the UK. METHODS: A cost-utility
model was constructed to simulate hypothetical patients with
PAH. Patients were assumed either to remain in FC III until
death or to deteriorate to FC IV where epoprostenol and pal-
liative care would be prescribed until death. It was further
assumed that the choice of ﬁrst-line treatment would not affect
the time to death, but instead would affect the duration patients
spend in FC IV. The time to deterioration in FC was approxi-
mated by time to clinical worsening (TTCW), a composite
measure of death or worsening of PAH leading to a change in
treatment. Data on TTCW was estimated from over three years
of observational data for bosentan and from published epide-
miological literature for palliative care alone. For epoprostenol,
TTCW was assumed equal to that of bosentan—in accordance
with published literature. The time horizon was that of patient
lifetime with only direct medical costs considered. The utility
associated with each FC was taken from published literature.
Costs and beneﬁts were discounted at 3.5% per annum. Proba-
bilistic sensitivity analyses were undertaken. RESULTS: Bosen-
tan dominated epoprostenol, as it provided the same number of
QALYs at a reduced cost. Bosentan dominated no active inter-
vention, as it had lower costs and greater QALYs, due to the
reduced time, per patient, spent in FC IV. CONCLUSION:
Bosentan is a more cost-effective ﬁrst-line therapy for patients
with PAH FC III in the UK than either epoprostenol or no active
intervention. It can be inferred that bosentan would also domi-
nate any other intervention with a TTCW not proven to be
better than palliative care alone.
PCV39
INDIRECT COMPARISONS OF RIVAROXABANVS
ALTERNATIVE PROPHYLAXES FORTHE PREVENTION OF
VENOUSTHROMBOEMBOLISM IN PATIENTS UNDERGOING
TOTAL HIP ORTOTAL KNEE REPLACEMENT
Diamantopoulos A1, LeReun C2, Rasul F1, Lees M3, Kubin M4
1IMS Health HEOR, London, UK, 2Carrigaline, Ireland, 3Bayer
HealthCare plc, London, UK, 4Bayer Healthcare AG,Wuppertal,
Germany
OBJECTIVE: To estimate differences in the efﬁcacy and safety of
rivaroxaban versus fondaparinux, warfarin and dabigatran in
prevention of venous thromboembolism (VTE). Such differences
may inﬂuence the cost-effectiveness of thromboprophylaxis
following total hip replacement (THR) or total knee replacement
(TKR). METHODS: Three large, randomized controlled trials
(RCTs; RECORD1–3) demonstrated relative risk reductions
Abstracts A197
